Identification and Validation of a Multigene Predictor of Recurrence in Primary Laryngeal Cancer

Elena Fountzilas1*, Vassiliki Kotoula2, Nikolaos Angouridakis3, Ilias Karasmanis3, Ralph M. Wirtz4*, Anastasia G. Eleftheraki5, Elke Veltrup4*, Konstantinos Markou3, Angelos Nikolaou3, Dimitrios Pectasides6, George Fountzilas1

1 Department of Medical Oncology, “Papageorgiou” Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece, 2 Department of Pathology, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece, 3 ENT Department, “AHEPA” Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece, 4 Siemens Healthcare Diagnostics, Cologne, Germany, 5 Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece, 6 Oncology Section, Second Department of Internal Medicine, “Hippokration” Hospital, University of Athens School of Medicine, Athens, Greece

Abstract

Purpose: Local recurrence is the major manifestation of treatment failure in patients with operable laryngeal carcinoma. Established clinicopathological factors cannot sufficiently predict patients that are likely to recur after treatment. Additional tools are therefore required to accurately identify patients at high risk for recurrence. This study attempts to identify and independently validate gene expression models, prognostic of disease-free survival (DFS) in operable laryngeal cancer.

Materials and Methods: Using Affymetrix U133A Genechips, we profiled fresh-frozen tumor tissues from 66 patients with laryngeal cancer treated locally with surgery. We applied Cox regression proportional hazards modeling to identify multigene predictors of recurrence. Gene models were then validated in two independent cohorts of 54 and 187 patients (fresh-frozen and formalin-fixed tissue validation sets, respectively).

Results: We focused on genes univariately associated with DFS (p<0.01) in the training set. Among several models comprising different numbers of genes, a 30-probe set model demonstrated optimal performance in both the training (log-rank, p<0.001) and 1st validation (p=0.010) sets. Specifically, in the 1st validation set, median DFS as predicted by the 30-probe set model was 34 and 80 months for high- and low-risk patients, respectively. Hazard ratio (HR) for recurrence in the high-risk group was 3.87 (95% CI 1.28–11.73, Wald’s p = 0.017). Testing the expression of selected genes from the above model in the 2nd validation set, with qPCR, revealed significant associations of single markers, such as ACE2, FLOT1 and PRKD1, with patient DFS. High PRKD1 remained an unfavorable prognostic marker upon multivariate analysis (HR = 2.00, 95% CI 1.28–3.14, p = 0.002) along with positive nodal status.

Conclusions: We have established and validated gene models that can successfully stratify patients with laryngeal cancer, based on their risk for recurrence. It seems worthy to prospectively validate PRKD1 expression as a laryngeal cancer prognostic marker, for routine clinical applications.

Introduction

Laryngeal cancer is the eleventh most common type of cancer in men worldwide. Every year 32,000 cases are newly diagnosed in Europe and 10,000 in the United States [1,2]. Despite the latest advances in diagnostic and therapeutic techniques, the majority of patients still recur after treatment [3]. Established clinicopathological factors cannot sufficiently predict patients that will recur. Additional factors are therefore required to accurately identify patients with poor prognosis. Expression profiling has been successfully used in the stratification of cancer patients with unfavorable prognosis [4,5,6,7]. Previous studies in head and neck cancer patients have linked gene expression profiles to nodal status [8,9,10], distant metastases [11,12] and disease-free survival [13,14,15,16]. While these studies provided great insight into the molecular complexity of head and neck cancer they did not identify a robust gene profile. The clinical use of these models has been limited by the large number of genes, the small-sized datasets and the lack of reproducibility and independent validation. Moreover, none of these studies focused exclusively on laryngeal cancer.
In the present study, we sought to identify genes prognostic of recurrence in patients with primary laryngeal cancer. The endpoint of our analyses was disease-free survival (DFS). We profiled tumor samples from two separate cohorts of patients using global gene expression profiling. Using the first cohort as a training set, we identified several prognostic gene models, which were then validated in the second cohort of patients. In order to further validate our results, we profiled selected genes of our models for relative expression with quantitative real-time polymerase chain reaction (qRT-PCR) in an independent cohort of patients.

Materials and Methods

Study population

Our study comprised of 307 patients diagnosed with primary squamous cell laryngeal carcinoma (training set: 66, 1st validation set: 54 and 2nd validation set: 187 patients), with median follow-up of 52, 33 and 89 months, respectively. All patients underwent surgical removal of the tumor at the Otorhinolaryngology Department of the AHEPA Hospital in Thessaloniki, Greece, between 1985 and 2008. Postoperative administration of radiation therapy was decided by the treating physician and most often was given to patients with positive tumor margins, patients with T4 tumors or those with T1/T2 supraglottic tumors for whom a prophylactic elective lymphadenectomy was not done. None of the patients received systemic therapy as part of their initial treatment. This is the current standard of care in many European countries [17], however this may not be the case in other countries, like the US, where the main focus is the preservation of the larynx with concurrent chemoradiotherapy, preceded in select cases by induction chemotherapy [18]. Follow-up included physical examination, every three months for the first three years and every six months thereafter. Imaging examinations were performed, as indicated by symptoms and physical examination. Detailed demographics and clinical characteristics for the patients with valid gene data are listed in Table 1, while individual patient data are shown as in Table S1.

Tumor specimens

Fresh-frozen tumor tissue samples, from patients comprising the training and 1st validation sets, were prospectively collected at the time of surgery, from 2004 to 2008, were immediately frozen in liquid nitrogen and stored at −80°C until processing. Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples, from patients comprising the 2nd validation set, were retrospectively collected (patients treated between 1985 and 2008). The latter were fixed in formalin for at least 6 hours before being embedded in paraffin. Laryngeal tumors were histologically assessed and verified in all cases, including the fresh-frozen tissue samples.

Ethics Statement

Fresh-frozen and FFPE tumor tissue samples were collected according to protocols approved by the Institutional Review Board of the “AHEPA” Hospital and the Bioethics Committee of the Aristotle University of Thessaloniki, School of Medicine. Written informed consent for the scientific use of biological material was obtained from all patients comprising the training and 1st validation sets and from the patients of the 2nd validation set treated after 2004. Waiver of consent was obtained from the Bioethics Committee for patients treated before 2004 and for whom FFPE tumor tissue samples needed to be retrospectively collected. All clinical investigations related to the present study have been conducted according to the principles expressed in the Declaration of Helsinki.

RNA isolation from fresh-frozen tissue and global gene expression profiling

RNA isolation from fresh frozen tumor specimens was performed using the RNeasy protocol (Qiagen, Hilden, Germany), as previously described [19]. RNA quantity was determined by measuring UV absorbance at 260 and 280 nm, while RNA quality was assessed using an Agilent 2100 Bioanalyzer RNA 6000 LabChip kit (Agilent Technologies, Palo Alto, CA). RNA was reverse transcribed, labeled and hybridized to Affymetrix (Santa Clara, CA) HG-U133A arrays, as previously described [19]. Experiments concerning the training and 1st validation sets were carried out separately, at different time points, at Siemens Healthcare Diagnostic Products (Cologne, Germany). The gene expression data have been deposited in the National Center for Biotechnology Information Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are available through the GEO Series accession number GSE27020. The following link has been created to allow review of GSE27020: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token = dxcdksausqicyz&acc = GSE27020

RNA isolation from FFPE tumor tissue samples and qRT-PCR

All investigations involving FFPE tissue samples were performed at the Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine. To validate the prognostic value of genes derived from our microarray analysis, we used a separate cohort of patients with available tumor tissue material. This sample group included 187 FFPE tissue samples that were macrodissected upon previous histological evaluation to contain >50% tumor cells. RNA was isolated after complete overnight tissue lysis using Trizol-LS (Life Technologies, Paisley, UK), as previously described [20] and was reverse transcribed with Superscript III (Life Technologies), according to the manufacturer’s instructions. cDNAs were normalized at 25 ng/ul and stored at −20°C until use. mRNA expression was investigated with FAM-labeled TaqMan® Gene Expression Assays in duplex reactions involving a primer-limited VIC-labeled reference assay for glucuronidase beta (GUSB, assay # Hs00939627_m1), as an endogenous template control. GUSB was preferred over usually applied endogenous controls because no pseudogenes have, as yet, been reported for this gene. Additionally, it has been identified as one among the best preserved mRNA targets in FFPE tissues [21]. qPCR mRNA target selection included evaluation of the 30 probes of the U133A signature for gene duplicates, gene characteristics (valid gene identities, type of gene, recorded splice variants, etc.), and expression levels using the C2 software. The reference cDNA sample (TaqMan® Control Total RNA, cat. no 4307281, Applied Biosystems) and no-template controls. The reference RNA was used as a positive plate control and for the evaluation of fold-change in gene expression. Out of the 30 U133A probes, 23 remained valid for qRT-PCR application (Table 2). For these 23 targets, we searched for pre-made TaqMan® Gene Expression Assays (Applied Biosystems) that would match the target sequences detected by the corresponding probes in the U133A array. It was possible to retrieve 16 such assays (Table 2). Duplex 10 ul reactions were run in duplicates, each containing 50 ng of template, in an ABI PRISM 7900HT system (Applied Biosystem/Life Technologies) on a 384-well block under default conditions involving 45 amplification cycles, along with a reference RNA sample (TaqMan® Control Total RNA, cat. no 4307281, Applied Biosystems) and no-template controls. The reference RNA was used as a positive plate control and for the evaluation of assay performance among runs (inter-run validation). Two of the 16 selected assays yielded deltaRQ values of >1.5 among different
runs and, hence, failed inter-run validation and were not further evaluated (Table 2).

Cycle thresholds (CT, corresponding to Cq in MIQE guidelines) for each target and for the endogenous reference were automatically obtained at default conditions and relative quantification (RQ) was calculated in a linear mode [22] by subtracting \((45-\text{avg } \Delta \text{CT})\), whereby 45 was the total amplification cycle number and \(\Delta \text{CT} = \text{average } [(\text{CT target}) - \text{CT GUSB}]\) for duplicates. Eligibility criteria for further sample evaluation included GUSB CT values of \(38\) for each reaction and \(\Delta \text{RQ}\) for each duplicate (intra-run variation) of \(\leq 0.8\). For 3 assays no amplification curves were obtained for the FFPE and the reference mRNA samples, while for an additional assay high intra-run RQ value differences were observed in 87% of samples (Table 2). Based on the above filtering steps for assay and sample eligibility, it was finally possible to evaluate RQ results for 10 genes only.

By applying the above criteria for sample eligibility, the following number of informative samples was obtained per mRNA target (informative assays only): ACE2, 159; DHTKD1 171; FLOT1, 178; MAP4K1, 169; NEK2, 156; SFRS8, 184; PRKD1, 162; TBC1D4, 165; TGOLN2, 183 and YTHDC2, 176.

### Statistical analysis

Prognostic gene expression models were developed exclusively in the training set. DFS was measured from the time of diagnosis until verified disease progression or death. Alive patients without verified disease progression were censored at the date of last contact. Genes selected had to be univariately associated with DFS \((p < 0.01, \text{Cox proportional hazard model})\). The algorithm fits proportional hazards models to relate DFS to each gene, one gene at a time, and provides a \(p\) value for each gene, testing the hypothesis that DFS is independent of the expression level of the particular gene. Genes found to be associated with DFS in the training set were then used in a multivariable model to assess their independent predictive power.
| Order | U133A probe set | Gene name | GB accession (U133A probe) | Gene symbol | Gene ID | Gene characteristics | Parametric p-value | Fold change | Assay employed | Reason for exclusion | GB Reference (qPCR assay) | Assay ID* | Ampliton size | Exon spanning | Accepted/ Failed |
|-------|-----------------|-----------|----------------------------|--------------|---------|---------------------|-------------------|-------------|----------------|-------------------|------------------------|-----------|---------------|---------------|------------------|
| 1     | 219962_at       | Angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 | NM_021804 | ACE2 | 59272 | 0.0660013 | 1.06 | yes | NM_021804.2 | Hs01085334_m1 | 83 | 18–19 | Accepted |
| 2     | 209916_at       | Dehydrogenase E1 and transketolase domain containing 1 | BC052477 | DHKD1 | 55526 | 0.0224942 | 1.12 | yes | NM_017965.5 | Hs01907842_g2 | 82 | 16–17 | Accepted |
| 3     | 208748_s_at     | Flotillin 1 | AK057012 | FLOT1 | 10211 | 0.3793981 | 0.96 | yes | NM_005903.2 | Hs01061949_g2 | 84 | 3–4 | Accepted |
| 4     | 214219_x_at     | Mitogen-activated protein kinase kinase 1 | BE694918 | MAPK1 | 11184 | splice variants | <1e-07 | 1.27 | yes | NM_0019460.0 | Hs01071814_m1 | 66 | 28–29 | Accepted |
| 5     | 211080_s_at     | NIMA (never in mitosis gene a)-related kinase 2 | AF208167 | NEK2 | 4751 | splice variants | 0.250279 | 0.25 | yes | NM_024917.2 | Hs01071227_m1 | 75 | 29–30 | Accepted |
| 6     | 206194_at       | Homeobox C6 | AW592266 | HOXC6 | 3223 | splice variants | 0.0086728 | 1.08 | yes | NM_004592.2 | Hs01092642_m1 | 60 | 4–5 | Accepted |
| 7     | 219103_at       | ArfGAP with SH3 domain, ankyrin repeat subfamily J, member 8 | BC039363 | SFRS8 | 6433 | splice variants | 0.0015481 | 0.87 | yes | NM_007181.4 | Hs01071227_m1 | 85 | 19–20 | Failed |
| 8     | 208384_at       | Trans-golgi network protein 2 | NM_006464 | TGN2 | 10618 | splice variants | 0.016105 | 0.96 | yes | NM_006464.2 | Hs01071227_m1 | 60 | 23–24 | Accepted |
| 9     | 206617_s_at     | Renin binding protein | NM_002742 | PRKD1 | 5587 | 0.0046131 | 0.95 | yes | NM_002742.2 | Hs01071227_m1 | 65 | 13–14 | Accepted |
| 10    | 213615_at       | Lysophosphatidylcholine acyltransferase 3 | AA744529 | MAP4K1 | 11184 | splice variants | 1.40E-06 | 1.18 | duplicate higher p-value | NM_001042600.1 | Hs01071227_m1 | 60 | 23–24 | Failed |
| 11    | 210257_x_at     | Cullin 4B | AW026461 | CUL4B | 8450 | splice variants | 0.0133109 | 0.94 | yes | NM_002910.5 | Hs00234138_m1 | 75 | 29–30 | Failed |
| 12    | 218103_at       | V-erb-b2 erythroblastic leukaemia oncogene homolog (avian-like) 2 | AI023864 | ACE2 | 59272 | 0.0015481 | 0.87 | yes | NM_014832.2 | Hs01071227_m1 | 85 | 19–20 | Failed |
| 13    | 214880_at       | Myeloid histone acetyltransferase 1 | AI030683 | HOXC6 | 3223 | splice variants | 0.0015481 | 0.87 | yes | NM_014832.2 | Hs01071227_m1 | 85 | 19–20 | Failed |
| 14    | 219102_at       | Myosin-activated protein kinase kinase 1 | AA744529 | MAP4K1 | 11184 | splice variants | 0.016105 | 0.96 | yes | NM_001042600.1 | Hs01071227_m1 | 60 | 23–24 | Failed |
| 15    | 215106_x_at     | Jun-moi domain containing 2B | AI030683 | JMD2B | 23010 | splice variants | 0.0015481 | 0.87 | yes | NM_014832.2 | Hs01071227_m1 | 85 | 19–20 | Failed |
| 16    | 203834_s_at     | Trans-golgi network protein 2 | NM_006464 | TGN2 | 10618 | splice variants | 0.016105 | 0.96 | yes | NM_010426.2 | Hs01071227_m1 | 75 | 23–24 | Failed |
| 17    | 205303_at       | Potassium inwardly-rectifying channel, subfamily K, member 8 | AI023864 | SFRS8 | 6433 | splice variants | 0.0015481 | 0.87 | yes | NM_007181.4 | Hs01071227_m1 | 85 | 19–20 | Failed |
| 18    | 214880_at       | Myeloid histone acetyltransferase 1 | AI030683 | HOXC6 | 3223 | splice variants | 0.0015481 | 0.87 | yes | NM_007181.4 | Hs01071227_m1 | 85 | 19–20 | Failed |

*Applied Biosystems/Life Technologies.

**High inter-run variations of the RQ values for the reference RNA sample (inter-run deltaRQ value range for the reference RNA (19 runs) and for 23 samples (monthly interval between runs) >1.5.**

(1)Complete absence of amplification curves in the reference RNA and/or in all study samples.

(2)High intra-run variability in deltaRQ values for study duplicates with amplified templates (duplicate deltaRQ >0.8).

doi:10.1371/journal.pone.0070429.t002
training set were then ranked based on their absolute hazard ratio value, provided by the algorithm. Prognostic gene models, comprising different numbers of top ranking genes, were developed using the supervised principal component survival algorithm [23]. The algorithm computes principal components and performs Cox proportional hazard regression analysis to calculate a regression coefficient (weight) for each principal component. A supervised principal component model is developed to provide a prognostic index for each patient of the study. A high prognostic index corresponds to a high value of hazard of recurrence. To evaluate the predictive value of this method, we used Leave-One-Out-Cross-Validation, where each case is omitted and the entire analysis is performed using the rest of the samples. In order to directly apply these models to the 1st validation set, we normalized the training and the 1st validation sets, using the empirical Bayes (EB) method [24]. The method uses an algorithm designed to adjust for the non-biological experimental variation (“batch effect”) between different datasets. It reduces inter-laboratory variation, as well as technical differences due to the utilization of different platforms and methodological approaches. After normalization, we directly applied the gene models to the 1st validation set without any modifications.

Kaplan-Meier curves and log-rank tests were used to estimate and compare the survival distributions in patients at high- and low-risk of recurrence. All reported $p$ values are two-sided. Cox proportional hazard analysis was used for univariate analysis and multivariate adjustment for known prognostic factors. Statistical analysis was performed using the BRB-ArrayTools developed by Dr. Richard Simon and the BRB-ArrayTools Development Team and the SPSS statistical package, version 18.0, (IBM Corporation, Armonk, NY).

We used the unsupervised “Subclass Mapping” (Submap) method [25] to evaluate the molecular correspondence of patients with favorable and unfavorable prognosis between the training set and the 1st validation set. This method bi-directionally assesses the association of predefined subtypes in multiple independent datasets, despite their technical variation. The algorithm provides the calculation of a $p$ value to demonstrate the likelihood of molecular similarity between the different subclasses, it is implemented in the GenePattern software (Version 3.0, Broad Institute, Cambridge, MA) and can be accessed at http://www.broad.mit.edu/genepattern/

Gene set analysis (GSA) was utilized to detect gene network deregulation characteristic of groups of patients with good or poor prognosis [26]. Using publicly available data, we then predicted oncogenic pathway activation status in each patient of the training and 1st validation sets. We applied gene expression models, previously developed and validated in vitro, to estimate the probability of pathway activation in each sample [27]. Finally, using Bayesian probit regression models we assigned to each patient a probability of pathway activation.

**Results**

**Identification and validation of prognostic classifiers using gene expression profiling**

The flowchart of our study is shown in Figure 1 (consort diagram). We analyzed primary laryngeal tumors from 66 patients (training set) and 54 patients (1st validation set) using global gene expression profiling. After evaluating the quality of the microarray data, we excluded 7 and 4 technical outliers from the two sets, respectively. For some of the genes, expression was evaluated using two different probe sets. Prognostic probe set models were identified exclusively in the training set. After excluding one fourth of the least variant genes, we focused on genes associated with DFS (Wald’s $p<0.01$). We then ranked the 253 probe sets found to be significantly associated with DFS, based on their Cox regression coefficient. We identified several prognostic probe set models consisting of as many as 250 to as few as 20 probe sets, which performed equally well in the training set.

Subsequently, we applied these multigene predictors directly to the 1st validation set. The 30-probe set model performed the best in the validation set (the model with the fewest genes demonstrating the highest statistical difference in DFS between high- and low-risk patients). Median DFS for the groups of patients with unfavorable and favorable prognosis, as predicted by the 30-probe set model, was 34 and 80 months, respectively (log-rank, $p=0.01$). The hazard ratio (HR) for recurrence in the high-risk group versus the low-risk group was 3.87 (95% CI 1.28–11.73, Wald’s $p=0.017$). Kaplan-Meier curves for all probe set models in the training and 1st validation sets can be found in File S1. Concordance between the risk assignments both in the training and 1st validation sets based on the different classifiers was high, 81–87% (Cramer V test = 0.62 to 0.75).
Annotations of all 30 probe sets included in our model are shown in Table 3, while a graphical representation of the gene expression patterns of the 30-probe set model in the high- and low-risk patients is shown in Figure 2a. We observed that in this model, two genes (ACE2 and MAP4K1) were represented by two probe sets. In order to avoid the effect of weighting these two genes twice as much compared to each of the other individual probe sets, representing a single gene, we retested our model in the training and 1st validation sets using a single probe set for each gene. In the training set, statistical significance in 28-gene model remained identical (log-rank test, \( p < 0.001 \), Figure 3a) with the one based on the 30-probe set model. Median DFS in the 1st validation set, as predicted by the 28-gene model, was 34 and 00 months, respectively (log-rank, \( p = 0.029 \), Figure 3b). The hazard ratio (HR) for recurrence in the high-risk group versus the low-risk group was 4.38 (95% CI 1.06–7.01, Wald’s \( p = 0.036 \)).

To further validate the prognostic significance of these profiles, we applied our 28-gene model to a publicly available cohort of patients with early stage laryngeal cancer [28]. Due to technical variation between the two datasets, 23 out of the 28 genes of our model were used to stratify patients based on their risk for recurrence. Despite the technical and biologic limitations (different platforms, different number of genes, early vs all-stage disease) our model maintained its prognostic significance. Median DFS for the groups of patients with unfavorable and favorable prognosis, as predicted by the 23-gene model, was 118 and 161 months, respectively (log-rank, \( p = 0.011 \), Figure S1). The HR for recurrence in the high-risk group versus the low-risk group was 4.37 (95% CI 1.24–15.34, Wald’s \( p = 0.022 \)).

### Table 3. 30-probe set model annotations.

| Probe set | Name | Symbol |
|-----------|------|--------|
| 202773_s_at | splicing factor, arginine/serine-rich 8 (suppressor-of-white-apricot homolog, Drosophila) | SFRS8 |
| 203387_s_at | TBC1 domain family, member 4 | TBC1D4 |
| 203834_s_at | trans-golgi network protein 2 | TGNL2 |
| 205303_at | potassium inwardly-rectifying channel, subfamily J, member 8 | KCNJ8 |
| 205836_s_at | YTH domain containing 2 | YTHDC2 |
| 205880_at | protein kinase D1 | PKD1 |
| 206194_at | homeobox C6 | HOXC6 |
| 206617_s_at | renin binding protein | RENBP |
| 208748_s_at | fliotillin 1 | FLTT1 |
| 209916_at | dehydrogenase E1 and transketolase domain containing 1 | DHTKD1 |
| 210257_x_at | cullin 4B | CUL4B |
| 211080_s_at | NIMA (never in mitosis gene a)-related kinase 2 | NEK2 |
| 213590_at | solute carrier family 16, member 5 (monocarboxylic acid transporter 6) | SLC16A5 |
| 213615_at | lysophosphatidylcholine acyltransferase 3 | LPCAT3 |
| 213906_at | v-myb myeloblastosis viral oncogene homolog (avian)-like 1 | MYBL1 |
| 214219_x_at | mitogen-activated protein kinase kinase kinase kinase 1 | MAP4K1 |
| 214339_s_at | mitogen-activated protein kinase kinase kinase kinase 1 | MAP4K1 |
| 214561_at | leukocyte immunoglobulin-like receptor pseudogene 2 | LIIRP2 |
| 214885_at | MYST histone acetyltransferase 1 | MYST1 |
| 215371_at | mediator complex subunit 27 | MED27 |
| 215616_s_at | jumonji domain containing 2B | JMJD2B |
| 216848_at | NA | NA |
| 217543_s_at | membrane-bound transcription factor peptidase, site 1 | MBTPS1 |
| 219103_at | ArfGAP with SH3 domain, ankyrin repeat and PH domain 3 | ASAP3 |
| 219464_at | carbonic anhydrase XIV | CA14 |
| 219719_at | HIG1 domain family, member 1B | HIGD1B |
| 219962_at | angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 | ACE2 |
| 222090_at | hypothetical protein LOC100134713 | LOC100134713 |
| 222257_s_at | angiotensin I converting enzyme (peptidyl-dipeptidase A) 2 | ACE2 |
| 38043_at | family with sequence similarity 3, member A | FAM3A |

To further validate the prognostic significance of these profiles, we applied our 28-gene model to a publicly available cohort of patients with early stage laryngeal cancer [28]. Due to technical variation between the two datasets, 23 out of the 28 genes of our model were used to stratify patients based on their risk for recurrence. Despite the technical and biologic limitations (different platforms, different number of genes, early vs all-stage disease) our model maintained its prognostic significance. Median DFS for the groups of patients with unfavorable and favorable prognosis, as predicted by the 23-gene model, was 118 and 161 months, respectively (log-rank, \( p = 0.011 \), Figure S1). The HR for recurrence in the high-risk group versus the low-risk group was 4.37 (95% CI 1.24–15.34, Wald’s \( p = 0.022 \)).

**Molecular homology of patients with favorable and unfavorable prognosis in the training and 1st validation sets**

Our 28-gene profile appears to not solely be a collection of prognostic genes but to actually capture the underlying biology of the tumors. To demonstrate the molecular homogeneity of high-risk tumors, we used subclass mapping (Submap), a method that assesses molecular similarity of predefined groups belonging to different datasets. We indeed illustrated that groups of patients with poor and good prognosis in the training set share the same biological patterns with the respective groups in the validation set,
above and beyond the expression of specific genes. Charts displaying good “molecular match” of the high- and low-risk patients are shown in Figure 2b.

Independent prognostic significance of the 28-gene model

We were interested in demonstrating the independent prognostic significance of our multigene predictor. We included in the analysis stage and grade, the only known prognostic factors, for which data were available for the patients of our study. We have also included radiation therapy, since it is known to significantly reduce local recurrence. In multivariate analysis, our 28-gene model maintained borderline prognostic significance in the 1st validation set. HR for recurrence in the high-risk group was 2.67 (95% CI 0.99–7.22, Wald’s \( p = 0.05 \)) (details are shown in Table 4).

Figure 2. Graphical representation of the 30-probe set model expression patterns (a) and Submap results (b). Graphical representation of the 30-probe set model expression patterns in patients with favorable and unfavorable prognosis is shown in panel a. Red color denotes overexpression and green color underexpression of the respective genes. Molecular similarity of patients with favorable and unfavorable prognosis in the training and 1st validation sets, using Submap, is shown in panel b. The bar below indicates the relationship between color and Bonferroni corrected \( p \) values. Red color represents high confidence for molecular homogeneity between the respective groups, while blue color represents lack of confidence thereof.

Figure 3. Kaplan-Meier survival estimates based on the 28-gene model risk predictions. Kaplan-Meier survival estimates for high- and low-risk patients based on the 28-gene model risk predictions in the training set (a) and 1st validation set (b).

\( p = 0.001 \)

\( p = 0.029 \)
Pathway analysis in the high- and low-risk groups

In order to gain some additional insight into the biological processes in patients with favorable and unfavorable prognosis, we performed Gene Set Analysis (GSA). We explored gene networks and biological themes, as described by the Kyoto Encyclopedia of Genes and Genomes (KEGG) Pathway Database. We indeed identified a wide range of pathways, differentially expressed between the two groups of patients (GSA Goeman’s global test \( p \) values < 0.01). We focused on pathways deregulated both in the training and in the 1st validation sets. Table 5 presents selected pathways of interest, while the full list of pathways can be found as in Table S2. Several of these pathways have previously been shown to play an important role in head and neck cancer progression. Interestingly, we observed that genes of the focal adhesion (FA) pathway [29], shown to be prognostic in our dataset, as well as in head and neck cancer, successfully stratified our patients based on their risk of recurrence (details in Figure 4).

Oncogenic pathway activation patterns in individual patients

In addition to the aforementioned pathway analysis results that derived from evaluating groups of patients, we sought to explore pathway activation in individual patients. We used previously developed and validated “in vitro” gene expression “read-outs” to identify activation of known oncogenic pathways in each patient of the training and 1st validation sets. We investigated the Src, Ras, \( \beta \)-catenin and E2F3 pathways, which have previously been shown to be associated with survival in other types of cancer [27]. Interestingly, we demonstrated that patients with poor prognosis more often had tumors characterized by Ras pathway activation, odds ratio (OR) = 2.92 (95% CI 1.33–6.39, Wald’s \( p \) = 0.01), while patients with good prognosis more often had tumors exhibiting Src and \( \beta \)-catenin pathway activation, OR = 4.54 (95% CI 1.64–12.50, \( p \) = 0.003) and 2.63 (95% CI 1.16 to 5.88, \( p \) = 0.03), respectively. In addition, we performed Cox proportional hazards survival regression and observed that the Ras pathway activation was found to be associated with poor prognosis, HR = 2.55 (95% CI 1.33–4.93, \( p \) = 0.0032).
CI 1.19–5.45, *p* = 0.020). The Src, β-catenin and E2F3 pathways did not appear to be associated with DFS in patients with laryngeal cancer. Corresponding Kaplan-Meier curves are shown in Figure 5. Finally, we performed multivariate analysis, including the 28-gene model and the Ras pathway and found that the predictor maintained its independent prognostic significance (Wald’s *p* = 0.001), as did the oncogenic pathway (Table 6).

qPCR validation of a subset of genes from the 28-gene predictor

The aforementioned analyses were performed using fresh-frozen tissue samples. However, this approach has certain methodological limitations when it comes to daily clinical practice. Thus, we attempted to validate our multigene predictor using qPCR on FFPE tumor tissue samples, a more easily applicable methodology. As described in the Materials and Methods section, however, it was possible to reliably investigate in our FFPE sample series the expression of only 10 of the 28 genes in the original predictor. The descriptive characteristics of RQ values obtained from the informative samples per assay are described in Table 7 (means, medians, SD, min, max). At first, we attempted to cluster continuous RQ values for all these genes. However, hierarchical clustering did not yield results comparable to the 28-gene predictor in a meaningful way, with the majority of high and low RQ values clustered in the opposite direction (Figures 6a and b). This was of no surprise, because we only examined 1/3 of the genes probed in the array signature, while fold-change in the expression of these genes was very narrow and could easily be reversed with a different method (qPCR vs. array hybridization) or a different type of material (FFPE vs. fresh-frozen tissues). Detailed analytical and statistical approaches for the behavior of each qPCR assay vs. the array probe in matched FFPE vs. fresh-frozen samples would be needed for the clarification of this discrepancy, however such an in-depth analysis was beyond the scope of the present study. Therefore, we next applied pre-determined profiling for the investigation of possible effects of the genes tested with qPCR on patient DFS. For this purpose, we transformed continuous RQ values into binary parameters (high/low expression). Based on the narrow fold-change of gene expression between the good and bad prognosis groups in the 28-gene predictor, we used median RQ values to classify high and low expression for the 10 evaluable genes. Log-rank testing for these genes as single markers yielded associations with outcome similar to those observed for the corresponding genes in the U133A signature (high/low patterns comparable with up- and down-regulation of gene expression, respectively, for 6 of the 10 genes), some of which were significant (PRKD1) or showed a trend for significance (ACE2, FLOT1) (Table 8). Hierarchical clustering of continuous RQ values for the latter three genes yielded two groups of patients
with significantly different DFS (Figures 6c and d). The expected gene expression pattern was present in the correct context with outcome, but was absent in the majority of cases.

Application of the good prognosis high/low gene expression patterns to the binary transformed RQ values revealed no single tumor with the expected pattern for all 10 genes. However, profiling of the three significant genes only revealed a strong association with patient outcome (univariate COX regression, overall Wald's $p = 0.012$). In particular, tumors expressing ACE2 high, FLOT1 and PRKD1 low (expected good prognosis profile according to the 30-gene predictor, $n=20$) were indeed associated with a significantly longer DFS, as compared to tumors expressing ACE2 low, FLOT1 and PRKD1 high (expected bad prognosis profile, $n=21$) (good vs. bad profile, HR = 0.24, 95% CI 0.09–0.63, Wald's $p = 0.003$). As with hierarchical clustering for the three genes, the majority of tumors ($n = 108$) did not fit into the above profiles and were of intermediate prognosis with a trend to perform better than the tumors expressing the bad profile (intermediate vs. bad HR = 0.58, 95% CI 0.33–1.03, Wald's $p = 0.063$). Similar results were obtained upon profiling PRKD1 with ACE2 (univariate Cox, overall Wald's $p = 0.006$; expected good vs. bad profile HR = 0.35, 95% CI 0.18–0.68, $p = 0.002$), and PRKD1 with FLOT1 (univariate Cox, overall Wald's $p = 0.013$; expected good vs. bad profile HR = 0.39, 95% CI 0.21–0.73, Wald's $p = 0.003$) (Figure 5, Table 8). A more detailed subclassification of tumors according to more combinations of high/low for the above genes did not yield significant associations with outcome.

With respect to clinicopathological parameters, no association was observed for age, alcohol consumption, smoking habits, histological grade, stage, or lymph node status, with ACE2, FLOT1 and PRKD1 mRNA as single binary variables, as clusters, or as pre-determined profiles. High ACE2 expression was observed more often in tumors without lymph node involvement (66 out of 137 [48.2%], as compared to tumors with positive lymph nodes (55 out of 130 [42.3%], Wald's $p = 0.015$).

Discussion

Our group has previously identified prognostic gene models in patients with early stage (T1N0M0, T2N0M0) laryngeal cancer [28] by using Illumina expression profiling (Illumina, CA) in 56 FFPE tissue samples. While this former study provided promising information on the genetic profile of early stage laryngeal cancer, herein we sought to expand our research to operable laryngeal cancer beyond stage. The present study employed a different platform for expression profiling (Affymetrix) and two independent validation sets. We observed that the prognostic profiles from our previous work do not share the same genes with the profiles presented here. However, the present 28-gene prognostic profile successfully stratified patients of the previously published early stage laryngeal cancer cohort with respect to disease-free survival (Figure S1). We believe therefore, that even though these profiles comprise of different genes, they capture the underlying biology of the tumors, which correlates with their aggressive behavior. Such a prognostic signature in laryngeal cancer patients has important clinical implications. Patients with unfavorable prognosis, as identified by our multigene predictor, might gain great

| Table 6. Univariate and multivariate analyses - Ras pathway. |
|-------------------------------------------------------------|
| **Univariate** | **Hazard Ratio (HR)** | **95% CI** | **Multivariate** | **Hazard Ratio (HR)** | **95% CI** |
| 28-gene model | <0.001 | 4.58 | 2.06 | 0.19 | 0.001 | 4.16 | 1.86 | 9.32 |
| Ras pathway | 0.020 | 2.55 | 1.91 | 5.45 | 0.036 | 2.26 | 1.06 | 4.85 |

| Table 7. Gene expression characteristics for the 10 evaluable mRNA targets investigated with qPCR in 187 FFPE samples. |
|-------------------------------------------------------------|
| **ACE2** | **DHTKD1** | **FLOT1** | **MAP4K1** | **NEK2** | **SFRS8** | **PRKD1** | **TBC1D4** | **TGOLN2** | **YTHDC2** |
| N (informative) | 159 | 171 | 178 | 169 | 156 | 184 | 162 | 165 | 183 | 176 |
| % (informative samples) | 85.03 | 91.44 | 95.19 | 90.37 | 83.42 | 98.4 | 86.63 | 88.24 | 97.86 | 94.12 |
| Mean | 38.8 | 46.3 | 47.03 | 45.63 | 39.37 | 47.62 | 44.25 | 44.68 | 46.95 | 46.11 |
| Median | 36 | 46.48 | 47.01 | 45.76 | 39.38 | 47.54 | 44.58 | 44.97 | 46.85 | 46.21 |
| Std. Deviation | 4.09 | 1.68 | 0.86 | 1.79 | 3.44 | 0.51 | 2.12 | 2.21 | 0.63 | 1.33 |
| Minimum | 32.26 | 36 | 44.81 | 36 | 33.49 | 46.02 | 36 | 35.27 | 45.4 | 36 |
| Maximum | 53.75 | 50.16 | 49.26 | 52.06 | 47.08 | 49.41 | 47.88 | 49.36 | 50.21 | 49.43 |

https://doi.org/10.1371/journal.pone.0070429.t006

https://doi.org/10.1371/journal.pone.0070429.t007
benefit from aggressive adjuvant treatment, while patients with favorable prognosis could be spared the side effects of what would appear to be an unnecessary treatment. Large-scale, prospective studies are needed however, to shed additional light into this matter and validate our findings.

Treatment efficacy of established therapeutic modalities could be further improved by novel therapeutic approaches. In an attempt to provide hypotheses on tumor progression, as well as novel therapeutic concepts, we explored the molecular biology of laryngeal tumors. First, using Submap, we illustrated that high- and low-risk tumors in the training set are molecularly homogeneous to their respective groups in the validation set. Then, using large-scale gene expression analysis, we demonstrated that tumors of high-risk patients are characterized by deregulation of several pathways of interest. Many of these gene networks have already been identified to be prognostic in cancer. Specifically, deregulation of the TGF-beta [30,31], VEGF [32,33,34], mTOR [35], Wnt [36], Hedgehog [37,38] and insulin [39] signaling pathways has been found to be associated with aggressive disease in squamous cell carcinomas.

Based on these data, the Hellenic Cooperative Oncology Group (HeCOG) proceeded with evaluating the prognostic value of the VEGF [40], EGFR [41] and insulin [42] signaling pathways in laryngeal cancer. Prospective validation of the prognostic role of the aforementioned pathways will promote the accurate identification of patients at high risk for recurrence who may necessitate a more aggressive treatment.

A number of studies also suggest that many of the genes playing a key role in these pathways may serve as novel therapeutic targets. For instance, in vivo studies in mice, targeting the mTOR [43] and IGF [44] molecules, have shown promising results for head and neck cancer treatment. Finally, it is important to outline the presence of the “Focal Adhesion” pathway in the gene set analysis results both in the training and 1st validation sets [29]. Thurlow et al have previously demonstrated the prognostic significance of this network, in patients with head and neck cancer.

To further explore networks in laryngeal cancer, we sought to examine pathway activation status in each individual patient of our study. The Ras pathway appeared to be more frequently activated in tumors from high-risk patients. More importantly,
Table 8. Individual and profiled gene expression effects on DFS.

| Gene expression in the good prognosis signature (30-gene predictor) | Concordance (trend) with the 30-gene predictor pattern |
|---------------------------------------------------------------|---------------------------------------------------|
| **ACE2**                                                      | **Up-regulated**                                  |
| Low                                                           | 0.070                                             |
| High                                                          |                                                  |
| **DHTKD1**                                                    | **Up-regulated**                                  |
| Low                                                           | 0.436                                             |
| High                                                          |                                                  |
| **FLOT1**                                                     | **Down-regulated**                                |
| Low                                                           | 0.068                                             |
| High                                                          |                                                  |
| **MAP4K1**                                                    | **Up-regulated**                                  |
| Low                                                           | 0.252                                             |
| High                                                          |                                                  |
| **NEK2**                                                      | **Down-regulated**                                |
| Low                                                           | 0.366                                             |
| High                                                          |                                                  |
| **PRKD1**                                                     | **Down-regulated**                                |
| Low                                                           | 0.012                                             |
| High                                                          |                                                  |
| **SFRS8**                                                     | **Up-regulated**                                  |
| Low                                                           | 0.400                                             |
| High                                                          |                                                  |
| **TBC1D**                                                     | **Up-regulated**                                  |
| Low                                                           | 0.193                                             |
| High                                                          |                                                  |
| **TGOLN2**                                                    | **Down-regulated**                                |
| Low                                                           | 0.360                                             |
| High                                                          |                                                  |
| **YTHDC2**                                                    | **Up-regulated**                                  |
| Low                                                           | 0.149                                             |
| High                                                          |                                                  |
| **ACE2/FLOT1/PRKD1**                                          | **N/A**                                           |
| Intermediate profile                                          | 0.009                                             |
| High/low/low/low                                              |                                                   |
| Low/high/high/high                                            |                                                   |

Multigene Predictors of Recurrence in Laryngeal Ca
there was a significant survival difference between patients with Ras pathway activation and those without. It has already been suggested that the Ras pathway plays a growth promoting role in head and neck cancer [45]. These data indicate that members of the Ras pathway may be valuable targets for chemotherapeutic interventions in laryngeal cancer.

In the present study, the identification and independent validation of multigene predictors was performed using fresh-frozen tumors from patients with resectable laryngeal cancer. However, gene expression profiling using microarray technology has several limitations that have as yet hampered its introduction into daily clinical practice. These include the need for fresh-frozen tissue, the lack of reproducibility and external validation, the complexity of microarray data analysis and cost. In an effort to transcribe our prognostic signature into clinically applicable markers, we tested genes from this classifier on a series of routinely processed FFPE samples from laryngeal cancer patients with similar disease characteristics at presentation. However, in order to evaluate the effectiveness of this validation step, as it is presented here, we need to consider that the 2nd validation set differed from the other two study groups in the type of tissue material used and the method applied for gene expression profiling. FFPE RNA quantification results may differ in comparison to those from fresh tissues [15,46], while microarray expression signatures are usually filtered down to a few genes for qPCR applications [47]. As a result, it is challenging to reproduce the significance obtained with array classifiers. For example, Mirisola et al developed a 4-gene classifier out of 213 genes distinguishing laryngeal carcinomas with and without relapse, but managed to reproduce only one of these gene markers with qPCR [15]. Herein, we applied very strict criteria for the selection of PCR targets in order to obtain profiles that would reliably reflect the ones included in the original U133 model. It should also be noted that, in comparison to the training and 1st validation cohorts, patients in the 2nd validation cohort experienced a higher incidence of recurrence. With all the above restrictions and reservations it was possible to validate profiles for 3 of the 28 genes in the array predictor, i.e., ACE2, FLOT1 and PRKD1. Despite the fact that 49–74% of tumors would fall into the intermediate category of undetermined prognosis, combinations of these markers might serve for distinguishing laryngeal cancer patients who would remain disease-free for more than 10 years or who would experience early relapse. Importantly, out of these three genes, PRKD1 was revealed to be an independent predictor for outcome. Hence, testing for PRKD1 expression only might, in fact, be more efficient for predicting laryngeal cancer prognosis than testing for all three genes. These are novel findings, since none of ACE1, FLOT1 and PRKD1 have previously been investigated in laryngeal or head and neck cancer, neither is it known whether these genes are functional in the normal laryngeal epithelium. The latter findings however, should be viewed as hypothesis generating rather than definitive.

From the biological point of view, the expression patterns of ACE2, FLOT1 and PRKD1 in association with good or bad prognosis are largely in line with the proposed anti-growth and anti-tumor roles for ACE2 [48,49]; with tumor promoting roles for FLOT1 [50,51]; and, with pro-metastatic roles for PRKD1 [52,53,54]. It should be noted, however, that the differences observed in the expression of ACE2, FLOT1 and PRKD1 in favourable and unfavourable laryngeal carcinomas were not clear-cut in the array predictor, which may reflect the lack of direct genomic alterations within the corresponding gene sequences. Determining RQ value cut-offs for prospective use remains a challenge with all qPCR expression markers of this type. Based on the present results, it seems worthy pursuing PRKD1 expression at
the protein level with immunohistochemistry for routine practice, provided that validated antibodies for this marker will become commercially available.

One potential criticism of the analyses presented here is that patients have been treated over a long period of time and that treatment modalities might have changed over these years. However, laryngeal cancer is a rare disease and it would be difficult to acquire a large number of samples from patients treated over a shorter period of time. Another limitation is that patients included in this study have been treated in a single institution. For this reason, one might question the applicability of our multigene predictors in diverse patient populations. Large-scale multicenter studies are therefore necessary to confirm the applicability of our prognostic models.

Moreover, all of our patients were treated with surgery, while approximately 40% of the patients also received radiotherapy. Of note, current treatment guidelines in many European countries [17], in early stages of laryngeal cancer, include surgical resection with or without adjuvant radiotherapy, which renders the findings of the present study both timely and clinically relevant. It is unclear however, whether patients with an unfavorable prognostic profile would be better treated with chemoradiotherapy, as given in other countries including the US [18], or other approaches. Prospective studies are needed in order to clarify this issue.

Conclusions

To summarize, laryngeal cancer is a heterogeneous disease. Patients with similar clinicopathological features may have a different outcome. It is important therefore, to accurately identify which patients with laryngeal cancer will recur, in order to use more aggressive and effective modalities. Our model accurately identified patients at high-risk for recurrence in the training set, as well as, in two independent validation sets. This model does not appear to solely be a collection of prognostic genes, but provides insight into disease mechanisms and potential therapeutic targets. The prognostic and biological significance of ACE2, FLOT1 and especially PRKD1 merits prospective validation, in order for these factors to possibly serve as independent prognostic markers for recurrence in patients with surgically resected squamous-cell carcinoma of the larynx.

Supporting Information

Figure S1 External validation of our 28-gene model using publicly available data. Kaplan-Meier survival estimates for high- and low-risk patients, as predicted by our 28-gene model in a separate cohort of patients with early stage laryngeal cancer. (DOC)

File S1 Kaplan-Meier survival estimates for high- and low-risk patients, as defined by prognostic models comprising 20 to 250 probe sets. (DOC)

Table S1 Detailed clinical characteristics for individual patients in the training set and the 1st and 2nd validation sets. (DOC)

Table S2 Gene set analysis in patients with poor and good prognosis in the training and 1st validation sets. (DOC)

Acknowledgments

We thank Dimitrios Spentzos for providing Elena Fountzilas with research tools and experience during her fellowship training. We also acknowledge Panagiota Konstantinopoulou for providing input on the utilization of samples and analysis of microarray data in earlier studies.

Author Contributions

Conceived and designed the experiments: EF AN GF. Performed the experiments: EF VK RMW EV. Analyzed the data: EF AGE. Contributed reagents/materials/analysis tools: NA IK KM AN DP GF. Wrote the paper: EF VK GF.

References

1. Ferlay J, Bray F, Pisani P, Parkin DM (2001) GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No 5, version 2.0 IARC Press, Lyon, France.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, et al. (2005) Cancer statistics, 2005. CA Cancer J Clin 55: 10–30.
3. Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck cancer. Lancet 371: 1093–1099.
4. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2117–2126.
5. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009.
6. Shen HY, Yu SL, Chen CH, Chang GC, Chen CY, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999–2009.
7. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, et al. (2002) A gene-expression signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356: 11–20.
8. O’Connell MJ, Lavery I, Youthers G, Paik S, Clark-Langene KM, et al. (2010) Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 28: 3937–3944.
9. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, et al. (2005) An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37: 182–186.
10. Carinci F, Arcelli D, Lo Muso L, Francisco F, Valenti D, et al. (2007) Molecular classification of nodal metastasis in primary larynx squamous cell carcinoma. Tranl Res 150: 233–245.
11. O’Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, et al. (2005) Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 24: 1244–1251.
12. Cromer A, Carles A, Million R, Ganguli G, Chalmel F, et al. (2004) Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis. Oncogene 23: 2494–2498.
13. Hensen EF, D Herdt MJ, Goeman JJ, Oosting J, Smit VT, et al. (2008) Gene-expression of metastasized versus non-metastasized primary head and neck squamous cell carcinomas: a pathway-based analysis. BMC Cancer 8: 168.
14. Chung CH, Parker JS, Karaca G, Wu J, Fuekhouser WK, et al. (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489–500.
15. Chung CH, Parker JS, Ely K, Carter J, Yi Y, et al. (2006) Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 66: 8210–8218.
16. Mirioti V, Mora R, Esposito AI, Guastini L, Tabacchiera F, et al. (2011) A prognostic multigene classifier for squamous cell carcinomas of the larynx. Cancer Lett 307: 37–46.
17. Ginos MA, Page GP, Michalowicz BS, Patel KJ, Volker SE, et al. (2004) Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res 64: 55–63.
18. Grognjac V, Lefebvre JL, Leizira L, Filip E (2010) Squamous cell carcinoma of the head and neck. EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 Suppl 5: v184–186.
19. Network NCC (2013) NCCN Guidelines Version 1.2013 Head and Neck Cancer. 2013.
20. Ihen M, Wirtz RM, Kalogeras KT, Mäde-Langosch K, Schmidt M, et al. (2010) Combination of osteopontin and activated leukocyte cell adhesion molecule as potent prognostic discriminators in HER2- and ER-negative breast cancer. Br J Cancer 103: 1048–1056.
20. Koletsa T, Kostopoulos I, Charalambous E, Christoforidou B, Nenopoulou E, et al. (2008) A splice variant of HER2 corresponding to Herstatin is expressed in the noncancerous breast and in breast carcinomas. Neoplasia 10: 687–696.

21. Sanchez-Navarro I, Gamez-Pozo A, Gonzalez-Baron M, Pinto-Marin A, Hardisson D, et al. (2010) Comparison of gene expression profiling by reverse transcription quantitative PCR between fresh frozen and formalin-fixed, paraffin-embedded breast cancer tissues. Biotechniques 48: 389–397.

22. Hemmig G, Gehrmann M, Stropp U, Brauch H, Fritz P, et al. (2010) Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem 56: 1845–1853.

23. Bair E, Tibshirani R (2004) Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2: E108.

24. Johnson WE, Li C, Rabinovic A (2007) Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8: 118–127.

25. Hoshida Y, Brunet JP, Tamayo P, Golub TR, Mesirov JP (2007) Subclass mapping: identifying common subtypes in independent disease data sets. PLoS One 2: e1195.

26. Goeman JJ, van de Geer SA, de Kort F, van Houwelingen HC (2004) A global test for groups of genes: testing association with a clinical outcome. Bioinformatics 20: 93–99.

27. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353–357.

28. Fountzilas E, Markou K, Vlachnis K, Nikolau A, Arapantoni-Dadioti P, et al. (2012) Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer. Ann Oncol 23: 2146–2153.

29. Thudlow JK, Pena Murillo CL, Hunter KD, Bufta FM, Patiari S, et al. (2010) Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol 28: 2881–2889.

30. Fukai Y, Fukuchi M, Masuda N, Osawa H, Kato H, et al. (2003) Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 104: 161–166.

31. Minicione G, Di Marcantonio MC, Artese L, Vianale G, Piccirelli A, et al. (2008) Loss of expression of TGF-beta1, TGF-beta2, and TGF-betaRII correlates with differentiation in human oral squamous cell carcinomas. Int J Oncol 32: 323–329.

32. Back SK, Jung KY, Lee SH, Woo JS, Kwon SY, et al. (2009) Prognostic significance of vascular endothelial growth factor-C expression and lymphatic vessel density in supraglottic squamous cell carcinoma. Laryngoscope 119: 1125–1130.

33. Onesto C, Hannoun-Levi JM, Chamorey E, Formento JL, Ramaoli A, et al. (2006) Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: correlation and prognostic significance. Br J Cancer 94: 1516–1523.

34. Shigyo H, Nosaka S, Katada A, Bandoh N, Ogino T, et al. (2007) Inducible nitric oxide synthase expression in various laryngeal lesions in relation to carcinogenesis, angiogenesis, and patients' prognosis. Acta Otolaryngol 127: 970–975.

35. Hirashima K, Baha Y, Watanabe M, Karashima R, Sato N, et al. (2010) Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol 17: 2486–2493.

36. Li AF, Hsu PK, Tzao C, Wang GC, Hung IC, et al. (2009) Reduced axin protein expression is associated with a poor prognosis in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol 16: 2486–2493.

37. Schneider S, Thurnher D, Kleinstein P, Leitner V, Petzelbauer P, et al. (2011) Expression of the Sonic hedgehog pathway in squamous cell carcinoma of the skin and the mucosa of the head and neck. Head Neck 33: 244–250.

38. Mor Y, Okumura T, Tsunoda S, Sakai Y, Shimada Y (2006) Gli-1 expression is associated with lymph node metastasis and tumor progression in esophageal squamous cell carcinoma. Oncology 70: 378–389.

39. Li S, Cha J, Kim J, Kim KY, Kim HJ, et al. (2011) Insulin-like growth factor II mRNA-binding protein 3: A novel prognostic biomarker for oral squamous cell carcinoma. Head Neck 33: 366–374.

40. Pentheroudakis G, Nicolaou I, Kotoula V, Fountzilas E, Markou K, et al. (2013) Cyclin D1, EGFR, and Akt/mTOR pathway: Potential prognostic markers in localized laryngeal squamous cell carcinoma. Strahlenther Onkol [Epub ahead of print].

41. Mountzios G, Kostopoulos I, Kotoula V, Sakanaih I, Fountzilas E, et al. (2013) Insulin-like Growth Factor 1 Receptor (IGFIR) Expression and Survival in Operable Squamous-Cell Laryngeal Cancer. PLoS One 8: e54048.

42. Nathan CO, Amirghahhari N, Gong X, Giordano T, ShiLe D, et al. (2007) Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer. Cancer Res 67: 2160–2168.

43. Barnes C, Oshiro K, Rayala SK, El-Naggar AK, Kumar R (2007) Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 13: 4291–4299.

44. Hao M, Davis NL, Ames SJ, Spanjaard RA (2002) Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 62: 7154–7156.

45. Ahmad D, Wing M, Schaub B, Triche T, Davicioni E (2010) Quantitative expression profiling in formalin-fixed paraffin-embedded samples by affinity microarrays. J Mol Diagn 12: 409–417.

46. Colman H, Zhang L, Sullivan EP, McDonald DM, Shooshtari NL, et al. (2010) A multigene predictor of outcome in glioblastoma. Neuro Oncol 12: 49–57.

47. Feng Y, Ni L, Wan H, Fan L, Fei X, et al. (2011) Overexpression of ACE2 produces antitumor effects via inhibition of angiogenesis and tumor cell invasion in vivo and in vitro. Oncol Rep 26: 1157–1164.

48. Feng Y, Wan H, Liu J, Zhang R, Ma Q, et al. (2010) The angiotensin-converting enzyme 2 in tumor growth and tumor-associated angiogenesis in non-small cell lung cancer. Oncol Rep 25: 941–948.

49. Punt S, Klokki T, Musa N, Jenstad M, Risberg B, et al. (2012) Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene [Epub ahead of print].

50. Tan C, Wu Z, Lin X, Yu C, Shi T, et al. (2011) Knockdown of FLOT1 impairs cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO1a. Clin Cancer Res 17: 3089–3099.

51. Eiseler T, Kohler C, Nimmagadda SC, Jamal A, Funk N, et al. (2012) Protein kinase D1 regulates Akt and promotes cell proliferation and tumorigenicity in breast cancer through upregulation of FOXO1a. Clin Cancer Res 18: 3134–3142.

52. Pust S, Klokk TI, Musa N, Jenstad M, Risberg B, et al. (2012) FLOT1 as a novel drug target in breast cancer. Breast Cancer Res Treat 136: 1111–1120.

53. Karam M, Legay C, Auclair C, Ricort JM (2012) Protein kinase D1 stimulates cell proliferation and tumorigenicity in breast cancer cells. Breast Cancer Res Treat 136: 1111–1120.

54. Sundram V, Chauhan SC, Jaggi M (2011) Emerging roles of protein kinase D1 in cancer. Mol Cancer Res 9: 983–996.